First Horizon Advisors Inc. Sells 97 Shares of Thermo Fisher Scientific Inc. $TMO

First Horizon Advisors Inc. lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.9% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,673 shares of the medical research company’s stock after selling 97 shares during the period. First Horizon Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $4,328,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC raised its position in Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after acquiring an additional 988 shares in the last quarter. Revolve Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of Thermo Fisher Scientific by 12.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 2,126 shares of the medical research company’s stock valued at $1,059,000 after purchasing an additional 235 shares during the period. Trek Financial LLC raised its stake in Thermo Fisher Scientific by 24.7% in the first quarter. Trek Financial LLC now owns 2,163 shares of the medical research company’s stock valued at $1,076,000 after buying an additional 429 shares during the period. Finally, Flossbach Von Storch SE raised its stake in Thermo Fisher Scientific by 5.8% in the first quarter. Flossbach Von Storch SE now owns 1,412,839 shares of the medical research company’s stock valued at $703,029,000 after buying an additional 77,554 shares during the period. Institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

TMO has been the topic of a number of research analyst reports. Evercore ISI increased their price target on Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Barclays increased their price objective on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. JPMorgan Chase & Co. increased their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday, October 9th. HSBC reissued a “hold” rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, Citigroup increased their price target on shares of Thermo Fisher Scientific from $500.00 to $580.00 and gave the company a “neutral” rating in a report on Thursday, October 23rd. Nineteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $601.65.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $567.68 on Thursday. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The firm’s 50-day simple moving average is $515.47 and its 200 day simple moving average is $460.61. The firm has a market cap of $213.28 billion, a price-to-earnings ratio of 32.79, a P/E/G ratio of 3.27 and a beta of 0.82. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. During the same period last year, the firm earned $5.28 earnings per share. The business’s revenue for the quarter was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 17,104 shares of the business’s stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $573.54, for a total value of $9,809,828.16. Following the completion of the transaction, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $65,247,057.48. The trade was a 13.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $574.15, for a total transaction of $229,660.00. Following the completion of the transaction, the executive vice president owned 21,152 shares of the company’s stock, valued at $12,144,420.80. The trade was a 1.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 36,420 shares of company stock worth $19,980,884. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.